Revance Therapeutics (RVNC) News Today → How this is some devastating news (From WealthPress) (Ad) Free RVNC Stock Alerts $3.02 -0.14 (-4.43%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | americanbankingnews.comHC Wainwright Trims Revance Therapeutics (NASDAQ:RVNC) Target Price to $11.00May 15, 2024 | americanbankingnews.comThe Goldman Sachs Group Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $8.00May 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by Piper SandlerMay 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Given New $12.00 Price Target at Needham & Company LLCMay 14, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at MizuhoMay 13, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $11.00 at HC WainwrightHC Wainwright lowered their target price on shares of Revance Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday.May 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 10, 2024 | finance.yahoo.comRevance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...May 10, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comRevance Therapeutics' (RVNC) "Overweight" Rating Reiterated at Piper SandlerPiper Sandler restated an "overweight" rating and issued a $11.00 target price (down from $20.00) on shares of Revance Therapeutics in a research report on Friday.May 10, 2024 | marketbeat.comMizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $8.00Mizuho decreased their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a "neutral" rating for the company in a research report on Friday.May 9, 2024 | msn.comRVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comRevance Therapeutics GAAP EPS of -$0.58, revenue of $51.94MMay 9, 2024 | businesswire.comRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateMay 9, 2024 | businesswire.comRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaMay 8, 2024 | markets.businessinsider.comRevance Therapeutics is about to announce earnings — here's what Wall Street expectsMay 3, 2024 | marketbeat.comRevance Therapeutics (RVNC) to Release Earnings on ThursdayRevance Therapeutics (NASDAQ:RVNC) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024May 2, 2024 | money.usnews.comRevance Therapeutics IncApril 14, 2024 | marketbeat.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 24.7% in MarchRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 13,550,000 shares, a growth of 24.7% from the March 15th total of 10,870,000 shares. Based on an average daily volume of 1,810,000 shares, the days-to-cover ratio is currently 7.5 days.April 12, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the companyApril 12, 2024 | businesswire.comRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingApril 9, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Stock Price Up 8.5%Revance Therapeutics (NASDAQ:RVNC) Trading 8.5% HigherMarch 27, 2024 | finance.yahoo.comRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Trading Up 4%Revance Therapeutics (NASDAQ:RVNC) Trading 4% HigherMarch 20, 2024 | insidertrades.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Insider Dwight Moxie Sells 8,125 SharesMarch 19, 2024 | marketbeat.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Insider Sells $40,950.00 in StockRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) insider Dwight Moxie sold 8,125 shares of the company's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $40,950.00. Following the completion of the transaction, the insider now directly owns 137,815 shares in the company, valued at approximately $694,587.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.March 16, 2024 | finance.yahoo.comRVNC Apr 2024 5.000 putMarch 12, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Shares Down 3.8% Revance Therapeutics (NASDAQ:RVNC) Trading Down 3.8%March 11, 2024 | msn.comRevance stock rises after CEO discloses share purchaseMarch 10, 2024 | marketbeat.comLazard Asset Management LLC Has $885,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Lazard Asset Management LLC trimmed its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 99.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 77,200 shares of the biopharmacMarch 7, 2024 | marketbeat.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and fouMarch 5, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Stock Price Up 7.7%Revance Therapeutics (NASDAQ:RVNC) Stock Price Up 7.7%March 4, 2024 | markets.businessinsider.comRevance Prices Offering Of 16 Mln Shares At $6.25/Share; Stock DropsMarch 4, 2024 | marketbeat.comEULAV Asset Management Increases Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)EULAV Asset Management lifted its position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 275.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 600,000 shares of the biopharmaceutical company's stock after purchasing an additional 440,0March 4, 2024 | marketwatch.comRevance Therapeutics Shares Slide After Public OfferingMarch 4, 2024 | markets.businessinsider.comRevance Proposes Public Offering Of $100 Mln Of Shares; Stock Down Over 8% In Pre-marketMarch 4, 2024 | msn.comRevance Therapeutics down 7%, prices $100M share offeringMarch 4, 2024 | finance.yahoo.comRevance Announces Pricing of $100.0 Million Public Offering of Common StockMarch 4, 2024 | businesswire.comRevance Announces Proposed Public Offering of Common StockMarch 2, 2024 | finance.yahoo.comUS$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest ResultsMarch 2, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comRevance Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) PT Raised to $9.00The Goldman Sachs Group boosted their target price on Revance Therapeutics from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday.February 29, 2024 | seekingalpha.comRevance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges RemainFebruary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)February 29, 2024 | marketbeat.comNeedham & Company LLC Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $18.00Needham & Company LLC cut their price target on shares of Revance Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday.February 29, 2024 | marketbeat.comBamco Inc. NY Has $11.70 Million Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Bamco Inc. NY trimmed its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 9.1% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 1,020,234 shares of the biopharmaceutical company's stock after selling 102,432 shares duFebruary 29, 2024 | finance.yahoo.comQ4 2023 Revance Therapeutics Inc Earnings CallFebruary 29, 2024 | markets.businessinsider.comRevance Therapeutics: Strategic Pivot and Growth Potential Justify Buy Rating Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. RVNC Media Mentions By Week RVNC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼-0.130.42▲Average Medical News Sentiment RVNC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼93▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLRN News Today PEPG News Today TBPH News Today ESPR News Today TRDA News Today FULC News Today NGNE News Today LXRX News Today KRRO News Today HRTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
